Harmony Biosciences (HRMY) Is Up 7.8% After Earnings Jump and Revenue Guidance Reaffirmed – What's Changed

• Harmony Biosciences Holdings recently reported second-quarter 2025 earnings, revealing net income of US$39.78 million versus US$11.59 million a year earlier and reaffirmed its full-year 2025 revenue guidance of US$820 million to US$860 million.
• This sharp improvement in earnings and maintained revenue outlook highlights the company’s operational momentum and management’s confidence in its ongoing business performance.
• With Harmony Biosciences delivering much higher profits and upholding its revenue outlook, we’ll examine how this earnings surge drives its investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Harmony Biosciences Holdings Investment Narrative Recap

To hold shares of Harmony Biosciences Holdings, an investor generally needs conviction in the ongoing strength of its core sleep disorder franchise and confidence that the company's current profitability and product pipeline can offset looming competitive and concentration risks. The recent surge in quarterly earnings, along with unchanged full-year revenue guidance, likely strengthens the company’s near-term outlook, but does not materially reduce heavy reliance on WAKIX or address future generic competition, factors that remain the most critical catalyst for upside and the biggest risk, respectively.

Most relevant to the latest earnings is the company’s reaffirmed 2025 revenue guidance of US$820 million to US$860 million, which points to steady demand for its main product while investors continue to seek evidence of meaningful progress in broadening the late-stage pipeline to reduce concentration risk. With increased profits but substantial dependence on one drug, Harmony’s story continues to revolve around...

Read the full narrative on Harmony Biosciences Holdings (it's free!)

Harmony Biosciences Holdings is projected to achieve $1.2 billion in revenue and $335.1 million in earnings by 2028. This assumes annual revenue growth of 17.1% and an earnings increase of $154.2 million from current earnings of $180.9 million.

Uncover how Harmony Biosciences Holdings' forecasts yield a $50.55 fair value, a 37% upside to its current price.

Exploring Other Perspectives

Six members of the Simply Wall St Community estimate Harmony’s fair value from US$50.55 to US$250.38, an especially wide spread. For many, the persistent risk of revenue concentration makes ongoing pipeline progress an area to watch closely when assessing future returns.

Explore 6 other fair value estimates on Harmony Biosciences Holdings - why the stock might be worth over 6x more than the current price!

Build Your Own Harmony Biosciences Holdings Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Harmony Biosciences Holdings research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Harmony Biosciences Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Harmony Biosciences Holdings' overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• The latest GPUs need a type of rare earth metal called Terbium and there are only 27 companies in the world exploring or producing it. Find the list for free.
• AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com